Summary
At present despite the statins we have, many do not reach goal. In fact. it may be that that goal is not adequate as we have still a major issue with cardiovascular disease. This product may prove to be a further advance along this line.
Analysis
Cardiovascular disease remains the number 1 killer in the US. Statins have improved ooutcomes but there is still much room for improvement. This drug may be such an advance.
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
